See more : NHC Foods Limited (NHCFOODS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Adial Pharmaceuticals, Inc. (ADIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adial Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lanthanein Resources Limited (LNR.AX) Income Statement Analysis – Financial Results
- Jack Technology Co.,Ltd (603337.SS) Income Statement Analysis – Financial Results
- Nippon Air conditioning Services Co., Ltd. (4658.T) Income Statement Analysis – Financial Results
- T2 Metals Corp. (AGLAF) Income Statement Analysis – Financial Results
- Yue Kan Holdings Limited (2110.HK) Income Statement Analysis – Financial Results
Adial Pharmaceuticals, Inc. (ADIL)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 564.00 | 60.50K | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| Gross Profit | -564.00 | -60.50K | -55.11K | -564.00 | -565.00 | -563.00 | -565.00 | -565.00 | -565.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 4.18M | 8.40M | 5.85M | 3.97M | 368.46K | 182.11K | 146.14K | 322.11K |
| General & Administrative | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Other Expenses | 0.00 | 0.00 | 46.49K | 2.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Cost & Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Interest Income | 69.78K | 63.34K | 6.54K | 32.50K | 95.23K | 7.39K | 367.00 | 240.00 | 1.26K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.17M | 144.54K | 9.64K | 0.00 | |
| Depreciation & Amortization | 564.00 | 564.00 | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| EBITDA | -7.00M | -13.32M | -19.46M | -10.93M | -8.15M | -6.98M | -994.35K | -410.00K | -817.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.89M | -13.32M | -19.29M | -10.93M | -8.24M | -6.99M | -995.29K | -410.81K | -819.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -113.94K | 585.21K | -1.82M | 35.00K | -346.53K | -4.64M | -144.17K | -9.39K | 1.26K |
| Income Before Tax | -7.00M | -12.73M | -19.52M | -10.89M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -502.00 | -94.08K | -32.50K | -76.06K | -3.48M | 367.00 | 9.64K | 1.26K |
| Net Income | -7.00M | -12.73M | -19.42M | -10.86M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| EPS Diluted | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| Weighted Avg Shares Out | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
| Weighted Avg Shares Out (Dil) | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Company...
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update...
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
Data merits further testing for pain reduction as a possible alternative to opioids
Adial Pharmaceuticals Provides Regulatory and Development Update
CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence related to its request for Fast Track...
Top 10 Biotech Penny Stocks to Watch in July 2021
Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information...
ADIL Stock Price Increases Over 30% Pre-Market: Why It Happened
The stock price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) increased by over 30% pre-market. This is why it happened.
Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer, and Dr. Bankole Johnson, Chief...
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern...
Adial to File Fast Track Application for AD04 with the FDA
CHARLOTTESVILLE, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an application for...
Adial Pharmaceuticals to Present at 23rd Annual ICR Conference
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial...
Source: https://incomestatements.info
Category: Stock Reports